GO
Loading...

Eli Lilly and Co

More

  • Final Glance: Pharmaceuticals companies Tuesday, 20 Jan 2015 | 6:36 PM ET

    Baxter International Inc. fell$. 20 or. 3 percent, to $71.81. Bristol-Myers Squibb Co. rose$. 14 or. 2 percent, to $62.45. Hospira rose$. 45 or. 7 percent, to $63.67.

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • Midday Glance: Pharmaceuticals companies Tuesday, 20 Jan 2015 | 1:33 PM ET

    Baxter International Inc. fell$. 16 or. 2 percent, to $71.85. Bristol-Myers Squibb Co. fell$. 17 or. 3 percent, to $62.15. Hospira fell$. 02 or percent, to $63.20.

  • Early Glance: Pharmaceuticals companies Tuesday, 20 Jan 2015 | 10:33 AM ET

    Baxter International Inc. fell$. 36 or. 5 percent, to $71.65. Bristol-Myers Squibb Co. rose$. 08 or. 1 percent, to $62.39. Hospira fell$. 47 or. 7 percent, to $62.75.

  • Final Glance: Pharmaceuticals companies Friday, 16 Jan 2015 | 6:19 PM ET

    Baxter International Inc. rose$. 53 or. 7 percent, to $72.01. Bristol-Myers Squibb Co. rose$. 68 or 1.1 percent, to $62.31. Hospira rose $1.70 or 2.8 percent, to $63.22.

  • Midday Glance: Pharmaceuticals companies Friday, 16 Jan 2015 | 1:19 PM ET

    Baxter International Inc. rose$. 32 or. 4 percent, to $71.80. Bristol-Myers Squibb Co. rose$. 21 or. 3 percent, to $61.84. Hospira rose$. 90 or 1.5 percent, to $62.42.

  • Early Glance: Pharmaceuticals companies Friday, 16 Jan 2015 | 10:13 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $71.11. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $61.47. Hospira fell$. 20 or. 3 percent, to $61.32.

  • Early movers: BAC, BBY, GOOG, APPL & more Thursday, 15 Jan 2015 | 8:28 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • *AstraZeneca sees $3.5 bln sales, analysts' numbers lower. *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

  • Martha Stewart ordeal changed me: Sam Waksal Tuesday, 13 Jan 2015 | 11:24 AM ET
    Sam Waksal of Kadmon Pharmaceuticals

    "Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.

  • SAN FRANCISCO, Jan 12- Eli Lilly and Co said on Monday that U.S. insurers are increasing pressure on the price of diabetes medications as they switch coverage from certain drugs to others to trim costs. "We've definitely seen increased price competition, more by payers than the companies themselves," Lilly Chief Financial Officer Derica Rice said on Monday in an...

  • 11 ways to play biotech Monday, 12 Jan 2015 | 6:59 PM ET

    Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile biotechnology space.

  • Your first trade for Monday Friday, 9 Jan 2015 | 5:56 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Early movers: COST, FDO, GOOG, HLF, GM & more Thursday, 8 Jan 2015 | 8:08 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 earnings and revenue just shy of Wall Street expectations. Lilly, which is betting on its rejuvenated pipeline of drugs, particularly for diabetes, oncology and animal health, forecast adjusted 2015 earnings of $3.10 to $3.20 per share.

  • Early movers: JCP, AXP, PEP, SNE, SIRI & more Wednesday, 7 Jan 2015 | 7:55 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Jan 7- Eli Lilly and Co, which has been battered in the past three years by competition from generics, forecast 2015 revenue shy of Wall Street expectations. The drugmaker expects sales of $20.3 billion to $20.8 billion for the year, it said on Wednesday. The company, which is betting on its rejuvenated pipeline of drugs particularly for diabetes, oncology and...

  • HALFTIME FINAL TRADES 1/6/15 Tuesday, 6 Jan 2015 | 2:35 PM ET
  • Early movers: CVEO, YHOO, NVS, GM, CLF & more Friday, 2 Jan 2015 | 7:45 AM ET
    NYSE exchange floor

    Some of the names on the move ahead of the open.